Background: To date, there has been no systematic study of DNA-based prenatal di-
| INTRODUCTION
Thalassemia is an inherited autosomal recessive disorder characterized by microcytic hypochromic anemia resulting from reduced or absent synthesis of one or more of the globin chains of hemoglobin.
1,2
There are two main types of thalassemia, α and β. 3, 4 The incidence of thalassemia is high among people living in parts of Mediterranean countries, the Middle East, Africa, and Southeast Asia, including southern China.
5
The major cause of α-thalassemia includes deletions that remove one or both α-globin genes from the affected chromosome 16. 5 The symptoms of α-thalassemia are caused by deletion or non-deletional mutation of one (-α/αα, α T α/αα, or αα T /αα) or both (-/αα or -α/-α) α-globin genes. Hb H (β 4 ) disease is caused by loss or inactivation of three α-globin genes (-/-α or -/α T α or -/αα T ). Severe anemia associated with Hb Bart's (γ 4 ) disease (-/-) can cause fetal death at the time of birth. 6 β-thalassemia is a group of diseases of hemoglobin, most of which result from point mutations or deletions within the β-globin gene on the chromosome 11. been identified in Chinese populations. 9 Parents who are carriers for the thalassemia gene may give birth to fetuses with major thalassemia.
Prenatal diagnosis can prevent the births of children with major thalassemia. Prenatal diagnosis of thalassemia is widely practiced using molecular biological technology.
The Hakka people are an intriguing Han Chinese populations that mainly inhabit southern China, which is characteristic of their unique culture and is distinct from the traditional culture of southern Hans, but show lots of similarities to that of Northern Hans, including some features in dialects, life styles, customs, and habits. 10 The prevalence of thalassemia in the Meizhou Hakka population in Guangdong Province of China is high. 11, 12 However, there has been no systematic study on DNA-based prenatal diagnosis of thalassemia in this area. Our study provides a retrospective analysis of fetuses from 279 pregnant Hakka women confirmed to have thalassemia using molecular prenatal diagnosis in Meizhou, Guangdong Province of China. Villi were washed twice with normal saline. Villus tissue was removed from 15 mL centrifuge tubes with hook tweezers, placed in
| MATERIALS AND METHODS
Petri dishes with saline. Parts of villi were removed from stripped maternal decidua with hooks at low magnification. Some of the tissues were used for the extraction of fetal DNA. The remaining villi were soaked in saline and frozen at −80°C.
17,18
Amniocentesis cells were isolated from 10 mL amniocentesis fluid using a centrifuge at 1000 g for 10 minutes. The supernatant was discarded and 800 μL sterile saline was used to resuspend cell pellets. Then 400 μL of pellet was removed for DNA extraction. 17, 19 As for samples of umbilical cord blood, 200 μL of umbilical cord blood was taken to extract DNA. Statistical analysis was conducted using SPSS 17.0 software (IBM, Armonk, NY, USA). The prevalence of thalassemia was evaluated using descriptive statistics.
| RESULTS
From January 2014 to December 2016, prenatal diagnosis was performed in 279 fetuses in 278 mothers. The age group for father and mother ranged from 19 to 48 years old and 16 to 42 years old, respectively. The mean gestational age at which this invasive procedure was carried out was 19.7±3.34 weeks. The parents with α-thalassemia showed Hb A 2 <3.5% or normal. The parents with β-thalassemia showed Hb A 2 over 3.5% and mean corpuscular volumes (MCV) of <80 fL.
Here, 279 fetuses from at-risk pregnancies were subjected to prenatal diagnosis. We tested 20 CVS samples, 255 amniocentesis fluid samples, and four cord blood samples ( (Tables 2 and 4) , and the 68 β-thalassemia families included 23 (33.82%) cases of severe thalassemia and 27 (39.71%) heterozygotes (Table 3 ). There were 12 cases with α+β-thalassemia, including three cases of severe β-thalassemia (Table 4 ).
There were no normal controls for individual loci in the kit we used. In this study, we detected a Cap+40-43 (-AAAC) homozygous mutation of β-thalassemia by sequencing (Fig. S1 ). The fetus inherited Cap+40-43 (-AAAC) mutations from his/her mother and father. The remaining parents chose to continue the pregnancy, and the infants showed no severe anemia during the first 6 months of follow-up after birth.
All the mothers who decided to terminate the pregnancy were followed up until termination, at which time tissues were examined and the diagnoses were confirmed. Cases of non-severe thalassemia showed no severe anemia phenotype within the first half year after birth, which was fully consistent with the results of prenatal diagnosis.
Our prenatal diagnosis proved to be highly accurate and reliable.
| DISCUSSION
Thalassemia is widely distributed in southern China, particularly in the Guangdong, Gunagxi, and Hainan Provinces. 23, 24 In Guangdong,
8.53% of the general population carries the α-thalassemia gene and 2.54% carries the β-thalassemia gene. chance of producing a fetus with Hb Bart's. 25 We identified 41 fetuses with Bart's hydrops syndrome, accounting for 25.79%. We also identified 41 fetuses with Hb Bart's hydrops syndrome and 23 cases with severe β-thalassemia. All these mothers decided to terminate their pregnancies. Altogether, the use of this test prevented the birth of 23
newborns with major β-thalassemia syndrome.
HbH disease can be divided into two types according to geno- were terminated. All other parents made the informed choice to continue the pregnancy. They showed no severe anemia phenotype within the first 6 months after birth and showed good growth upon follow-up.
We identified two fetuses with Hb Bart's disease and one fetus with deletion Hb H disease. In all three cases, one parent was an α-thalassemia carrier and the other was an α+β-thalassemia carrier.
These results indicate fetuses at risk for being homozygous for α-thalassemia. We suggest that it should be considered standard to test for α-thalassemia mutations in the β-thalassemia gene when the other partner in the couple is also an α-thalassemia carrier because there is a one-in-four chance that they will produce a fetus with Hb Bart's or Hb H disease.
At first, to eliminate the risk of maternal cell contamination (MCC), we performed two rounds of DNA analysis. The first analysis was performed after amniocentesis or CVS, and the second analysis was carried out after fetal DNA was re-extracted from amniocyte or CVS after culture. When we used STR detection technology to rule out maternal cell contamination, we performed two rounds of DNA analysis after confirming that there was no maternal cell contamination. Using these methods, we successfully minimized the risk of maternal cell contamination to guarantee the accuracy and reliability of the results.
21
The term invasive prenatal diagnosis refers to obtaining fetal material by CVS, amniocentesis, or cordocentesis. Mutations in the α- In conclusion, we here conducted a systematic study of DNAbased prenatal diagnoses of 279 fetuses in at-risk pregnancies to in parents thalassemia in the Meizhou, a very high-incidence area 
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